Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

Xenon Pharmaceuticals (NASDAQ:XENE) had its target price boosted by Deutsche Bank Aktiengesellschaft from $56.00 to $90.00 in a research report released on Tuesday morning,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on XENE. Wolfe Research started coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 target price on the stock. Wells Fargo & Company increased their price target on Xenon Pharmaceuticals from $48.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Chardan Capital upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Robert W. Baird lifted their price objective on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, JPMorgan Chase & Co. upped their price objective on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $71.94.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ:XENE opened at $60.61 on Tuesday. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of -13.90 and a beta of 0.91. The firm has a fifty day moving average price of $42.95 and a 200 day moving average price of $41.56. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the company posted ($0.84) EPS. As a group, research analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at $32,000. Blue Trust Inc. raised its holdings in Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter worth $33,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Xenon Pharmaceuticals in the third quarter worth $39,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 topline results show azetukalner produced a statistically significant reduction in focal‑onset seizure frequency, positioning the drug for an NDA submission targeted in Q3 2026 — a major clinical milestone that drove the earlier sharp rally. GlobeNewswire: X-TOLE2 Results Reuters: Trial Meets Main Goal
• Positive Sentiment: Multiple brokerages raised price targets and maintained bullish ratings (HC Wainwright, Deutsche Bank, Needham, Wells Fargo, Wedbush), reflecting upwardly revised sales and valuation assumptions after the Phase 3 readout. Benzinga: Analyst Upgrades
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement, indicating the exchange processed material news that subsequently drove heavy intraday activity. (News pending/halt was lifted following the topline release.)
• Neutral Sentiment: Yesterday’s massive intraday rally — driven by the trial news — created rapid re‑rating and higher volatility; that squeeze can produce follow‑through profit‑taking and larger volume swings. 247WallSt: Big One‑Day Gain
• Negative Sentiment: Xenon announced a proposed underwritten public offering of $500M of common shares (with a 30‑day option for an additional $75M). Issuing new equity after a large run‑up creates dilution risk and puts selling pressure on the stock even though proceeds could fund commercialization and ongoing trials. GlobeNewswire: Offering MSN: Offering Coverage

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.